New Haven’s Kolltan Pharmaceuticals has appointed Dr. Carolyn F. Sidor as senior vice president and chief medical officer.
Sidor, who most recently worked as a biotech consultant after serving as CMO and senior vice president for Maryland-based EntreMed and vice president at Cato Research Ltd. in North Carolina.
In her new role, she will lead the development of Kolltan’s lead drug candidate, KTN3379, a monoclonal antibody for treating cancer and other maladies. The company’s first clinical trial is anticipated to begin in mid-2014.
